Business Context and Reporting Period
Company: Indaptus Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 11, 2026
Reporting Period: Event date February 11, 2026
The Company entered into material definitive agreements regarding the repricing of warrants issued during financing rounds in 2024 and 2025. This filing serves as solicitation material for a special stockholder meeting scheduled for February 26, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure adjustments related to warrant exercise prices.
Material Changes
- Warrant Repricing (Executing Holders): The Company entered into agreements with holders of 913,638 warrants to reduce exercise prices from a range of $8.30 to $47.60 down to $1.75 per share.
- Warrant Repricing (Unilateral): The Board of Directors unilaterally reduced the exercise price of an additional 762,787 warrants (including placement agent warrants) to $1.75 per share.
- Price Floor: The new exercise price of $1.75 represents the "Minimum Price" calculated in accordance with Nasdaq rules.
- Voting Agreement: As a condition for the repricing, Executing Holders agreed to vote all shares held in favor of proposals at the special stockholder meeting on February 26, 2026.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that all other terms and provisions of the warrants remain unchanged aside from the exercise price reduction. The Company urges investors to read the Definitive Proxy Statement for important information regarding the proposals at the upcoming special meeting.
Risks and Contingencies: The filing notes that the Company and its management are deemed "participants" in the solicitation of proxies. It highlights that the interests of these participants may differ from those of shareholders generally, directing investors to the Proxy Statement filed on January 21, 2026, for details on executive compensation and related person transactions.
Investor Verification Checklist
- Verify the total number of shares potentially issuable upon exercise of the repriced warrants (1,676,425 total).
- Confirm the dilution impact of the reduced exercise price ($1.75) on existing shareholders.
- Review the Definitive Proxy Statement (filed January 21, 2026) for details on the proposals to be voted on February 26, 2026.
- Examine the Voting Agreement (Exhibit 10.2) to understand the specific voting commitments made by the Executing Holders.
- Check the Company's cash position to assess the ability to fund operations given the capital structure changes.